The U.S. Drug Administration Committee supports the provision of Pfizer's new crown vaccine to children aged 5 to 11 years old

　(Fighting New Coronary Pneumonia) The US Drug Administration Committee supports the provision of Pfizer's new crown vaccine to children aged 5 to 11 years old

　　China News Agency, Washington, October 26 (Reporter Sha Hanting) The US Food and Drug Administration (FDA) expert committee voted on the 26th local time to support the provision of Pfizer's new crown vaccine to children aged 5 to 11 under emergency authorization.

　　On the same day, the FDA expert committee voted for the provision of Pfizer vaccines to children aged 5 to 11 with 17 votes in favor, 0 votes against, and 1 abstention.

The expert committee believes that the benefits of providing new crown vaccines to children of this age in preventing new crown pneumonia outweigh the potential risks.

　　For the 5-year-old to 11-year-old group, Pfizer said it will provide two doses of the new crown vaccine, the dose is one-third of the adult.

Pfizer said that studies have shown that the dose is sufficient for vaccine protection and hopes to reduce side effects.

　　Amanda Cohn, a member of the committee and an expert at the Centers for Disease Control and Prevention (CDC), said that people in this age group should have access to vaccinations that other age groups have.

"We don't want children to die of new coronary pneumonia, and we don't want children to be admitted to the ICU (Intensive Intensive Care Unit)."

　　According to CDC statistics, among the 5 to 11-year-old age group, 8,300 people have been hospitalized due to new coronary pneumonia, of which about one-third are in the intensive care unit, and the death toll is close to 100.

　　On the same day, a number of expert committee members said that although they support the provision of new crown vaccines to this group, they oppose the mandatory vaccination of this group.

Some experts believe that only children aged 5 to 11 years old who are at high risk should be vaccinated against the new crown.

　　Next, the FDA will decide whether to approve the provision of new crown vaccines to children aged 5 to 11 years under emergency authorization.

The FDA usually follows the opinions of its expert committees.

　　At present, the FDA has fully approved the use of Pfizer's new crown vaccine in people aged 16 and over.

For the 12 to 15-year-old group, the FDA has approved its use under emergency authorization.

(over)